Advanced Therapy Medicinal Products (ATMPs) are medicinal products based on gene therapy, somatic cell therapy or tissue engineering. Regulation (EC) No 1394/2007 has been designed to ensure their free movement within the European Union (EU), to facilitate their access to market and to foster European competitiveness while guaranteeing the highest level of health protection for patients. Academic GMP facilities are major contributors to the development of ATMPs. This study was designed to assess the impact of Regulation (EC) No 1394/2007 and related Directives on them. Respondents were gathered by accessibility sampling. 747 European contact points in academic and non-industrial facilities were identifi ed. Of these, 85 responded to a fi rst survey and 50 to a longer questionnaire. Experienced centers were selected in every member state and approached with semi-structured interviews. Successful Academic and Hospital GMP facilities can be identifi ed, independent of the country of origin. However, the implementation of EU Regulation is highly heterogeneous between member states, with evidence of substantial diff erences in the criteria used to defi ne ATMPs and in the approved manufacturing environment. In ATMP Development and Manufacture, academic institutions fi ll an ill-defi ned gap where commercialisation is improbable, such as rare diseases or highly patient-specifi c therapies. Investigator-initiated trials of ATMPs critically depend on academic GMP facilities, as does the biopharmaceutical industry which mostly uses these trials as its pipeline. However, EU legislators do not engage with Academia when considering new legislation. We have found evidence of poor harmonisation at the level of delivery across the Member States and uncertainty about the regulatory process; stifl ing development and commercialisation of these therapies. Most disturbing is the detrimental eff ect on translation to early phase trials which remain largely academic investigator-led. Academic GMP practitioners should strengthen their political visibility and contribute to the development of functional and eff ective EU legislation in this fi eld.
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Challenges in quality management in haematopoietic stem cell transplant (HSCT) in a resource poor setting (Nigeria) E.X. Iyamah, G.N. Bazuaye University of Benin Teaching Hospital Edo State Nigeria (Benin, NG) Objective: A good quality control involves conformance to specifi cations or standards which is a detailed instruction required to perform a procedure. The fi rst HSCT was performed in Nigeria in September 2011 with several challenges in quality management.
Method: Challenges include;Absence of standards quality regulatory groups: -Unlike most developed countries like Europe where there is a regulatory body like JACIE, in Nigeria there is no regulatory group to regulate the practice of HSCT. Lack of trained quality management personnel. Only the coordinator has some training with JACIE on quality control but there is no designated trained quality manager to ensure unbiased quality control. Inadequate data management and SOP-The hospital is yet to computerize the data in the hospital with many procedures not having SOP and this has a negative impact on the quality of HSCT. Non availability of quality blood products-blood donation in Nigeria is mainly commercial and it is diffi cult to ensure that irradiated blood products transported to and from another centre 300km away has good quality. Low quality of drugs -the quality of some drugs supplied in Nigeria may not be good quality and this may negatively aff ect the quality of HSCT. Quality of stem cells:-Stem cells were estimated from total nucleated cells viability and quality was diffi cult to assess. Results: Recently the Nigerian group for blood and marrow transplant was set up to set up guidelines to regulate HSCT in Nigeria. A quality manager has been appointed and currently undergoing training at Basel Hospital Switzerland. The department has a data manager who is collaborating with the data managers in EBMT to improve data management in Nigeria. Medical students are encouraged to be voluntary donors. We now have a functional irradiation unit and a fl ow cytometry to assess levels of CD34. We now have the services of direct importation of drugs from the companies to reduce fake drugs and all procedure must have SOP. Conclusion: There are several challenges in quality management in poor resource country. However with a regulatory group, a trained quality manager and a group of staff willing to follow standard protocol, the quality of HSCT will gradually improve to international standard.
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Challenges in laboratory services in haematopoietic stem cell transplantation (HSCT) in a developing country: Nigeria O. Eguae, E.X. Iyamah, I. Asemota, C. Enogun, G.n. Bazuaye University of Benin Teaching Hospital Edo State Nigeria (Benin, NG) Objective: Heamatopoietic Stem Cell Transplantation ( HSCT) has been practiced in developed countries over years but only started in Nigeria by 2011. An eff ective laboratory service is important for the success of HSCT. In developing countries like Nigeria there are several challenges encountered during the fi rst HSCT. Method: challenges include: Lack of trained personnel-Only one laboratory scientist is currently trained for HSCT. Inadequate/non functional equipment-Most laboratories in the hospitals have inadequate equipment due to poor resources in Nigeria. Inadequate power supply-This makes storage of samples and products diffi cult and leads to damage of laboratory equipment. Blood products supply-Blood donation is mainly commercial and blood products was irradiated in another hospital 300km away. Cross matching is still manual and not automated. Bone marrow harvesting/processing; There was no bone marrow harvest bag stand, stem cells were estimated from total nucleated S511 cells and no facility to separate the total bone marrow extract into CD34 cells, plasma and red cells. It was also diffi cult to determine the viability of the harvested stem cells. Lack of fungal & viral studies; The hospital do not have facilities for fungal and viral studies. Results: The center has sent out another laboratory scientist for training in Switzerland and we carried out in-training of laboratory scientist in the hospital six months before the fi rst HSCT. The hospital have made plans for more equipment and provided standby generators as alternate power supply. Medical students were encouraged as voluntary blood donors and we now have a functional irradiation unit. We have procured fl ow cytometry machine to assess CD34 cell counts and hope to procure a machine to separate harvested Bone marrow extract. We are yet to procure facilities to carry out fungal and viral studies. Patients are therefore placed on prophylaxis antifungal and antiviral. Conclusion: The laboratory support in a developing HSCT centre like Nigeria should gradually improve to international standard. However we had eff ectively utilized available equipment to ensure a successful fi rst HSCT. Regenerative medicine, which among other areas encompasses cellular therapies and tissue engineered products, is seen as a key future industry for the UK. Central to NHSBT's future role in regenerative medicine is the expansion of Stem Cell & Immunotherapies (SCI) services, allowing SCI to develop and manufacture future cell therapies that go beyond the 'minimally manipulated' cell products that are the mainstay of current BMT practice. NHSBT SCI already operates at 7 UK sites, consisting of HTA licenced, JACIE accredited cell processing facilities serving regional BMT programmes. In addition to the fi rst Advanced Therapy Unit (ATU), opened in 2011 at Liverpool, NHSBT aims to have an additional 3 ATU sites holding licences from the MHRA for Cell therapy Investigational Medicinal Products and "Specials" manufacture, operational by Q3 of 2013 with planned further integration with the Clinical Biotechnology Centre (CBC) at Bristol, allowing NHSBT to manufacture GMP grade molecular therapies and gene vectors. The national network of SCI/ATU facilities will be supported by integrated infectious disease, bacteriology, red cell immunology, tissue typing, national logistics and cold chain supply support, Tissue Services and Specialist Therapeutic Services (STS), all covered under the umbrella of an overarching Quality Management System (QMS). Future success in the development of novel cellular and molecular therapies for human application is dependent on multi-disciplinary teams but the development and integration of a supported ATU network, within a single QMS, is not without its challenges. Challenges to the development of a national ATU network will be discussed at both a local and national level including areas such as GMP facility design, staff training, raw material handling (qualification, supplier audit, goods-in, quarantine/release), temperature controlled transport logistics, safety testing (infectious disease, bacteriology), design of new processes for project evaluation and project management, Quality Assurance and Qualifi ed Person resourcing and integration of external testing organisations within a quality management plan. Along with the development of facilities and staff , future bioprocessing and clinical technologies will also play a key role together with further challenges around the integration of clinical trial manufacturing involving externally grant funded academically led collaborations.
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O1457 The construction of a new cleanroom for the processing of tissues and cells: lessons Learnt J. Fitzgerald Our Lady's Children's Hospital, Crumlin (Dublin, IE)
A new cleanroom was required to be constructed at Our Lady's Children's Hospital, Crumlin in order to comply with the requirements of the Tissues and Cells Directives (2006/23/EC) to replace
S512 an existing facility. The process involved the design, construction and validation of the new cleanroom on a very restricted site within the exising hospital campus. Where possible, the design included contingency to future-proof against future developments and an expansion of the anticipated workload. Many lessons were learnt during the process which could be incorporated in future similar builds.
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How to maintain JACIE accreditation: a single programme experience
Objectives: Since the achievement of JACIE Accreditation a number of advantages have been obtained by implementing a quality management system (QMS). However, the quality system maintenance and its development can be as, or more, complex than implementing the system itself. Methods: We obtained the maintenance of the QMS through application of ISO standards: self-evaluation, audits, collection and analysis of indicators, meetings, management of deviation, documents revision, evaluation of performance, management review. Results: Every six months self-evaluation checklist of QMS is fi lled in by the Quality Supervisor (QS) by interviewing key-personnel. If there is a lack of compliance an improvement plan is drawn up. QS carries out internal audits on transplant processes and on clinical records; once a year the QMS is audited by the Responsible of Quality of the Hospital. Activity and quality indicators for monitoring the Program's performance are collected and analyzed compared with defi ned threshold values (table 1) . Periodical meetings are arranged for: clinical discussion; physicians and nurses continuing education; transplant scheduling and QMS. Twice a year QS organizes a large scale collection of deviations in the Clinical Unit. All reports are analyzed and if necessary corrective/preventive actions are planned. Once a year or often all QMS documents are revised by staff that check the compliance of the procedures. If the SOP is still valid no change is made. Otherwise the SOP is modifi ed, validated and released. Performance evaluation: assessment questionnaires are prepared and fi lled by nurse staff on diff erent activities (e.g.: chemotherapy administration, stem cells infusion). The results are used for planning training or retraining activity. The Program should normally review its QMS at least every 12 months. This review should include all the above mentioned elements. The results are recorded and included decisions/actions for improving the QMS for the next year. Conclusion: Once the JACIE Accreditation has been achieved, strategies should be implemented to maintain an appropriate QMS. This is crucial to overcome a progressive decline of interest that along with the lack of time and the absence of feedback between the Clinical Unit with the Processing and Collection Facilities may represent an important threat to keep the clinical and laboratory standards requested by JACIE. We have generated software which allows our research myeloma database to incorporate all ongoing panoramic data, of biochemistry haematology etc that is generated in routine clinical
practice, into its standard snapshot data (disease parameters, treatments etc). Access to ~ 2.8 x 10 6 of retrospective and realtime data items can be utilised for myeloma research and in-house to support the multidisciplinary team (MDT) with dayto-day patient care planning and delivery, quality assurance and practice management. improve the service quality of our facility, a quality management system was developed. To ensure all functions within CTF are covered by our quality management system, we created our quality management system based on an eight component approach. In line with this approach, we have created nine diff erent quality documents. These nine documents make up our Quality Manual (QM) and collectively they provide the summary and detailed description of our quality management system. A fl ow diagram describing the fl ow of quality documents that make up our QM can be found in diagram 1 below. Purpose/Objective: The purpose of our quality management system is to ensure all functions within CTF are covered, with the aim to improve our overall service quality, which will then translate to better product quality and safety. Conclusion: Our facility has since under gone PIC/S cGMP and JACIE onsite inspection and hopefully awarded accreditation and cGMP licence by April 2013. Apart from allowing international bench marking, the introduction of quality management system in our facility has also allowed us to identify potential weakness as well as to introduce continuous improvement within our system. The format of the quality management system also supports the internal audit system, as audit can now be conducted in eight segments, thus allowing for ease of audit planning as well as complete and holistic review of the systems in any audit cycle. Processing Laboratory(CPL). These parts represent complex TP with a single Quality Management System.To evaluate the quality of the TP we defi ned QIs common to the whole TP and then specifi c to each part. Common QIs contain:system for document control(operating manual, forms and SOP´s), continual education and training of personnel, adverse event reporting. These QIs are annually audited and analyzed during the Quality Management Meetings(QMM). QIs in the CU were defi ned as follows: overall survival(OS) after SCT, transplant-related mortality(TRM) day+100 and 1year, epidemiological situation and SCT with microbially positive graft. QIs for the CPL include analysis of contaminated products, time to engraftment, quantifi cation of CD34 + cells and graft processing complications(comp). Quality Indicators in AU are defi ned as: comp.during leukapheresis(LP) and bone marrow harvests(BMH), the yields of LP and lymphocytapheresis(LC). Data are regularly analyzed during QMM and in regular audits, the results are compared with internationally published data and with previous years. In 2012, a total of 9 audits of key areas of the TP were performed. Audits were carried out with satisfactory results(3/9) and satisfactory with minor defi ciencies(6/9), proposed corrective actions have been implemented. Within CU OS and TRM after SCT were analyzed, the results are not signifi cantly diff erent in comparison with the year 2011 and with published data. Epidemiological situation was concluded as good compared to the previous year. show a good quality of care whole TP at our institution.
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P1464 Competency assessment techniques R. Brown Imperial College Healthcare NHS Trust (London, GB)
It is important that staff are capable and can understand written procedures that they must follow which involves their job. This is also a requirement under JACIE and local legal requirements in the UK such as the HTA & MRSA. But how does one verify this and produce evidence? At Imperial College Healthcare NHS Trust, Haematology department Standard Operating Procedures (SOPs) ALL have a Competency Assessment (CA) inbuilt into them. These either take the form of written tests or practical observations that reference the content of the procedure or theoretical practice. CAs are created by the author of the SOP due to their direct experience. CAs are kept short and simple though where the procedure or practice has important steps, these are especially highlighted in the CA to determine that staff have understood these key requirements. Imperial College has two types of CAs, ten questions with a combination of multiple choice answers or a true/false statement. The other type of CA is by shadowing an experienced member of staff in that technique and then observing the trainee on a number of procedures, who is then deemed competent once the assessor is confi dent. Answers for the question type of CAs are stored in a restricted electronic location. Once the SOP is reviewed and signed off by staff , CAs are done by the reviewers to ensure understanding and implementation. The author and the quality management team are the only exceptions. When SOPs are issued relevant staff are made aware and then complete the CA. Staff who may answer include the Programme Director, Consultants, Managers, Head nurse, etc. These CAs are then marked by the Quality team or Author, the pass mark needed is 80%. If this is not met, staff are asked to re-read and re-do the assessment with the Quality team or Author or Nurse Educator. For archiving the Quality team retain the marked CAs of the reviewers of the SOP. Nursing staff have a competency matrix issued to them, this is checklist of the procedures they must do. CAs are then fi led with the matrix in a secure place on the wards by the nurse educator, thus enabling audits against HTA and JACIE guidelines regarding staff competency and levels of education, this means competency can be evaluated over time.
The question arises how often should staff competency be reassessed? At Imperial College we do this each time a procedure is updated and has a major change (generally every two years). Ideally we are aiming to re-assess every time a procedure is up versioned for a major or minor change. Results are good but improvable and CCBB staff for 2013 decided to strengthen the Search Engine Optimization in order to increase the number of contacts by web, to include CCBB's website link on Regione Calabria's website and, fi nally, to spread website address through social networks.
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How to know the exact number of your GMP MSC preparation? S. Budelli, G. Spaltro, M. Viganò, C. Lavazza, E. Montelatici, T. Montemurro, B. Baluce, L. Lazzari, R. Giordano Fondazione IRCCS Ca' Granda -Ospedale Maggiore Policlinico (Milan, IT) Mesenchymal stem cells (MSCs) have emerged as a major celltherapy approach with a diverse spectrum of clinical applications in regenerative medicine. The production of MSCs should satisfy the requirements of GMP rules governing medicinal products and specifi cations for release testing should include identity, purity, impurities, sterility, potency, cell viability and total cell number.
In particular, in order to guarantee the correct cell dose required in clinical trials, it becomes extremely relevant to fi nd an univocal method for cells count. Moreover, it is crucial also to achieve more reproducible and effi cacious outcomes for MSC-based therapies and allow comparability of results. In our hospital-based GMP facility we produce MSCs from different sources, such as bone marrow (BM), cord blood (CB) and adipose tissue (AD), and we validated every analytical procedure to demonstrate standardization and compliance with pre-defi ned requisites of quality. We describe the validation of an automated method for cell counting (NucleoCounter, Chemometec) and its correlation in terms of reliability, accuracy and precision to the manual method already used in our facility, i.e. Burker chamber. This automated cell counting device is based on principles of fl uorescence microscopy for determining cell number and viability by staining DNA with propidium iodide immobilized inside a charger cassette. The coeffi cient of variation (CV%) between the automated and manual methods was found be less than 20%. We also found that the Burker chamber determinations are less accurate than the automated ones (R 2 >0,9), as the CV% between each replicate is greater. The high CV% found in the Burker chamber doesn't appear to be operator-dependent as the reproducibility of the method between diff erent operators is confi rmed by a very low CV% (5%). The analyzes conducted in this validation have been included in the Investigational Medicinal Product Dossier of all the MSCsbased products currently provided by our institution in several phase I/II clinical trial already ongoing. Lgs: 2010-01-25, n.16 , and the Joint Accreditation Committee Euro-ISHAGE/EBMT (JACIE) guidelines are applied in our facility, built by SOL Group SpA in 2006, to assure cryopreserved haematopoietic stem cell transplantation (HSCT) the maximum high-standard security conditions. Methods: The cryobanking area, with access limited by a badge reader, is provided with 2 dewars for storage, 2 nitrogen pressurized tanks, a double-speed ventilation system directly connected with 2 oxygen detectors, acoustic and visual alarms placed inside/ outside the cryobank, a watch dog button for operator's safety, a Medical Device software, based on a Programmable Logic Controller (PLC), which manages automatic fi lling of dewars, ventilation system, oxygen detectors and supervises/transmits local/ remote alarms. GAMP-validated CryoManagementCM software (SW) registers critical informations about reagents and supplies used to cryopreserve HSCT, the unit characteristics and real position inside dewars, quarantine and allows a 24 hours monitoring and backup recording of storage temperature and nitrogen level in the dewars. Results: In six years of cryobanking activity, we registered 350 new samples and the following alarms of: low/high temperature in dewars (n°15), low/high nitrogen level in dewars (n°6), breaking temperature probes (n°2), time out fi ll of dewars (n°3), watch dog for staff safety (n°5), low oxygen level (n°2). The CryoManagementCM SW satisfi es traceability requirements. A Planned Preventative Maintenance allows to produce the cryobanking top shape: every six months all areas are inspected and eventually repaired by SOL specialists. A Disaster Plan was specifi ed to prevent failures: uninterruptable power supply (UPS) protects from power breakdowns, Watch Dog Personal Computer (PC) alarm announces, by an automatic phone dialer, PC crashdown and SOL Group keeps for us 1 tank and 1 dewar as a back-up. A Disaster Recovery Plan provides for us the 24/7 availability of technical qualifi ed support of SOL specialists, to drag dewars and samples in a dedicated SOL cryobank, with temperature safeguard. Conclusions: The reasons of all described alarms have not aff ected cryopreserved bags and the staff health. Only with a strict collaboration between specifi c professional services, is possible to realize and maintain the maximum highstandards for our samples.
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To achieve and maintain high competence and knowledge regarding paediatric stem cell transplants among nurses A.-L. Gustafsson, A. Pilström Children´s Cancer Center (Gothenburg, SE) The Pediatric Oncology Center at The Queen Silvia Children´s Hospital is one of Swedens six pediatric oncology centers. The unit investigate, diagnose and treat children with oncology diagnoses. Within the oncology unit there is a section where 15-20 stem cell transplants(SCT) for children 0-18 years are conducted annually. The purpose with the improvement project is to achieve and maintain a high competence and knowledge regarding pediatric SCT among nurses. A plan for achieving and maintaining the SCT competence among nurses at ward has been established. An experienced tutor accompanies the nurse during the introduction. During the later part of the unit introduction the SCT coordinator provides basic information. The objective is to give the nurse basic knowledge about SCT. During the fi rst year each nurse goes through training with reference to current PM's.The purpose with this education is to provide basic knowledge about pediatric SCT-care. After a year the nurse is given the opportunity to be responsible for a transplant patient. Prior to this the SCT coordinator provides the nurse with clinical instructions at the ward. The purpose is specifi c knowledge of SCT care. In order to support the nurses keeping up their SCT knowledge the SCT drivers license is available as an interactive education. There are three levels. Level 1 SCT base is basic knowledge connected to the introduction phase at the unit. Level 2 SCT care is one year experienced nurses expected level of knowledge. Level 3 SCT advanced is for very experienced nurses with several years of working with SCT. The drivers license class is sent via email to the nurse and can be taken when convenient. The class provides instant feedback making it an interactive tool for learning. The idea is to give the nurse S518 input on areas in need of improvement. Continuous updates with new relevant issues is easily attached and therefor a new and improved way of implementing new and updated routines and provide follow up information regarding nurses comprehension of the information. The nurses who completed the license appreciated the new way of learning and says "it is good that there are comments on whether it was right or wrong, you learn new things," "it's a perfect way to keep up to date" A continuous plan for providing and maintaining the high SCT competence is of great importance. In the learning process the interactive follow up with the drivers license is a new tool for maintaining the high competence required for nurses working within the pediatric SCT unit.
